Levofloxacin inhalation - Horizon Pharma

Drug Profile

Levofloxacin inhalation - Horizon Pharma

Alternative Names: Aeroquin; Inhaled levofloxacin hemihydrate - Horizon Pharma; MP 376; Quinsair

Latest Information Update: 12 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mpex Pharmaceuticals
  • Developer Adare Pharmaceuticals; Horizon Pharma
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • Preclinical Bronchiectasis; Mycobacterial infections
  • Discontinued Respiratory tract infections

Most Recent Events

  • 24 May 2017 Levofloxacin inhalation solution (QUINSAIR™) licensed to Chiesi Farmaceutici SpA in Europe, the Middle East and Africa (EMEA) regions
  • 22 Dec 2016 Launched for Cystic fibrosis-associated respiratory tract infections in Canada (Inhalation)
  • 22 Dec 2016 Adverse events data from clinical studies in Cystic fibrosis-associated respiratory tract infections released by Horizon Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top